Annual CFO
-$12.33 M
+$3.58 M+22.50%
March 1, 2024
Summary
- As of February 8, 2025, GRCE annual cash flow from operations is -$12.33 million, with the most recent change of +$3.58 million (+22.50%) on March 1, 2024.
- During the last 3 years, GRCE annual CFO has risen by +$1.99 million (+13.87%).
- GRCE annual CFO is now -548.42% below its all-time high of -$1.90 million, reached on February 1, 2010.
Performance
GRCE Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$4.24 M
-$643.00 K-17.88%
September 1, 2024
Summary
- As of February 8, 2025, GRCE quarterly cash flow from operations is -$4.24 million, with the most recent change of -$643.00 thousand (-17.88%) on September 1, 2024.
- Over the past year, GRCE quarterly CFO has dropped by -$2.35 million (-124.05%).
- GRCE quarterly CFO is now -3210.05% below its all-time high of $136.30 thousand, reached on February 1, 2013.
Performance
GRCE Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$11.81 M
-$2.13 M-21.94%
September 1, 2024
Summary
- As of February 8, 2025, GRCE TTM cash flow from operations is -$11.81 million, with the most recent change of -$2.13 million (-21.94%) on September 1, 2024.
- Over the past year, GRCE TTM CFO has increased by +$1.76 million (+12.94%).
- GRCE TTM CFO is now -1366.79% below its all-time high of -$805.50 thousand, reached on May 1, 2009.
Performance
GRCE TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
GRCE Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +22.5% | -124.0% | +12.9% |
| 3 y3 years | +13.9% | -23.3% | +28.8% |
| 5 y5 years | +50.2% | +30.7% | +12.8% |
GRCE Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +28.4% | -124.0% | +32.1% | -21.9% | +38.6% |
| 5 y | 5-year | at high | +50.2% | -140.8% | +40.4% | -21.9% | +58.6% |
| alltime | all time | -548.4% | +50.2% | -3210.1% | +50.3% | -1366.8% | +58.6% |
Grace Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$4.24 M(+17.9%) | -$11.81 M(+21.9%) |
| Jun 2024 | - | -$3.60 M(+72.2%) | -$9.69 M(-21.4%) |
| Mar 2024 | -$12.33 M(-22.5%) | -$2.09 M(+10.4%) | -$12.33 M(-9.1%) |
| Dec 2023 | - | -$1.89 M(-10.5%) | -$13.57 M(-11.9%) |
| Sep 2023 | - | -$2.11 M(-66.1%) | -$15.40 M(-7.9%) |
| Jun 2023 | - | -$6.24 M(+87.6%) | -$16.73 M(+5.1%) |
| Mar 2023 | -$15.91 M(-7.7%) | -$3.33 M(-10.6%) | -$15.91 M(+1.2%) |
| Dec 2022 | - | -$3.72 M(+8.2%) | -$15.73 M(-5.2%) |
| Sep 2022 | - | -$3.44 M(-36.6%) | -$16.59 M(-13.8%) |
| Jun 2022 | - | -$5.43 M(+72.5%) | -$19.26 M(+11.8%) |
| Mar 2022 | -$17.23 M(+20.4%) | -$3.15 M(-31.4%) | -$17.23 M(+8.7%) |
| Dec 2021 | - | -$4.58 M(-24.9%) | -$15.85 M(+2.4%) |
| Sep 2021 | - | -$6.10 M(+79.5%) | -$15.48 M(+14.2%) |
| Jun 2021 | - | -$3.40 M(+93.2%) | -$13.55 M(-5.4%) |
| Mar 2021 | -$14.32 M(-37.6%) | -$1.76 M(-58.2%) | -$14.32 M(-7.4%) |
| Dec 2020 | - | -$4.21 M(+0.9%) | -$15.46 M(-15.8%) |
| Sep 2020 | - | -$4.18 M(+0.2%) | -$18.35 M(-9.6%) |
| Jun 2020 | - | -$4.17 M(+43.7%) | -$20.30 M(-11.6%) |
| Mar 2020 | -$22.95 M(-7.4%) | -$2.90 M(-59.2%) | -$22.95 M(-19.7%) |
| Dec 2019 | - | -$7.11 M(+16.2%) | -$28.58 M(+1.0%) |
| Sep 2019 | - | -$6.12 M(-10.3%) | -$28.30 M(+3.6%) |
| Jun 2019 | - | -$6.82 M(-20.0%) | -$27.33 M(+10.3%) |
| Mar 2019 | -$24.79 M(+155.7%) | -$8.53 M(+24.8%) | -$24.79 M(+27.3%) |
| Dec 2018 | - | -$6.83 M(+32.8%) | -$19.47 M(+20.7%) |
| Sep 2018 | - | -$5.15 M(+20.2%) | -$16.13 M(+26.9%) |
| Jun 2018 | - | -$4.28 M(+33.5%) | -$12.71 M(+31.1%) |
| Mar 2018 | -$9.69 M(+85.8%) | -$3.21 M(-8.3%) | -$9.69 M(+49.4%) |
| Dec 2017 | - | -$3.50 M(+103.2%) | -$6.49 M(+51.9%) |
| Sep 2017 | - | -$1.72 M(+36.0%) | -$4.27 M(+31.9%) |
| Jun 2017 | - | -$1.27 M(-1.4%) | -$3.24 M(-32.0%) |
| Mar 2017 | -$5.22 M | - | - |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Nov 2016 | - | -$1.28 M(+86.0%) | -$4.76 M(+1.9%) |
| Aug 2016 | - | -$690.10 K(-56.6%) | -$4.67 M(-17.5%) |
| May 2016 | - | -$1.59 M(+32.5%) | -$5.66 M(+16.7%) |
| Feb 2016 | -$4.85 M(-15.7%) | -$1.20 M(+0.4%) | -$4.85 M(-10.3%) |
| Nov 2015 | - | -$1.19 M(-28.9%) | -$5.41 M(-10.6%) |
| Aug 2015 | - | -$1.68 M(+116.6%) | -$6.05 M(-0.2%) |
| May 2015 | - | -$776.10 K(-55.9%) | -$6.07 M(+5.5%) |
| Feb 2015 | -$5.75 M(-5.9%) | -$1.76 M(-4.3%) | -$5.75 M(-29.4%) |
| Nov 2014 | - | -$1.84 M(+8.4%) | -$8.15 M(+14.5%) |
| Aug 2014 | - | -$1.70 M(+267.2%) | -$7.12 M(+25.6%) |
| May 2014 | - | -$461.60 K(-88.9%) | -$5.67 M(-7.4%) |
| Feb 2014 | -$6.12 M(+145.6%) | -$4.16 M(+415.2%) | -$6.12 M(+235.3%) |
| Nov 2013 | - | -$806.60 K(+232.6%) | -$1.82 M(+14.1%) |
| Aug 2013 | - | -$242.50 K(-73.4%) | -$1.60 M(-42.3%) |
| May 2013 | - | -$911.20 K(-768.5%) | -$2.77 M(+11.2%) |
| Feb 2013 | -$2.49 M(-55.9%) | $136.30 K(-123.5%) | -$2.49 M(-38.7%) |
| Nov 2012 | - | -$580.50 K(-58.9%) | -$4.06 M(-38.7%) |
| Aug 2012 | - | -$1.41 M(+123.7%) | -$6.62 M(+13.1%) |
| May 2012 | - | -$631.90 K(-55.9%) | -$5.85 M(+3.7%) |
| Feb 2012 | -$5.65 M(+195.0%) | -$1.43 M(-54.4%) | -$5.65 M(+25.2%) |
| Nov 2011 | - | -$3.14 M(+387.7%) | -$4.51 M(+72.7%) |
| Aug 2011 | - | -$644.80 K(+51.6%) | -$2.61 M(+18.3%) |
| May 2011 | - | -$425.20 K(+44.1%) | -$2.21 M(+15.2%) |
| Feb 2011 | -$1.91 M(+0.7%) | -$295.10 K(-76.3%) | -$1.91 M(-0.2%) |
| Nov 2010 | - | -$1.25 M(+418.6%) | -$1.92 M(+51.8%) |
| Aug 2010 | - | -$240.20 K(+79.8%) | -$1.26 M(+2.8%) |
| May 2010 | - | -$133.60 K(-55.3%) | -$1.23 M(-35.3%) |
| Feb 2010 | -$1.90 M | -$298.90 K(-49.5%) | -$1.90 M(+18.6%) |
| Nov 2009 | - | -$591.30 K(+186.6%) | -$1.60 M(+58.4%) |
| Aug 2009 | - | -$206.30 K(-74.4%) | -$1.01 M(+25.6%) |
| May 2009 | - | -$805.50 K | -$805.50 K |
FAQ
- What is Grace Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Grace Therapeutics?
- What is Grace Therapeutics annual CFO year-on-year change?
- What is Grace Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Grace Therapeutics?
- What is Grace Therapeutics quarterly CFO year-on-year change?
- What is Grace Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Grace Therapeutics?
- What is Grace Therapeutics TTM CFO year-on-year change?
What is Grace Therapeutics annual cash flow from operations?
The current annual CFO of GRCE is -$12.33 M
What is the all time high annual CFO for Grace Therapeutics?
Grace Therapeutics all-time high annual cash flow from operations is -$1.90 M
What is Grace Therapeutics annual CFO year-on-year change?
Over the past year, GRCE annual cash flow from operations has changed by +$3.58 M (+22.50%)
What is Grace Therapeutics quarterly cash flow from operations?
The current quarterly CFO of GRCE is -$4.24 M
What is the all time high quarterly CFO for Grace Therapeutics?
Grace Therapeutics all-time high quarterly cash flow from operations is $136.30 K
What is Grace Therapeutics quarterly CFO year-on-year change?
Over the past year, GRCE quarterly cash flow from operations has changed by -$2.35 M (-124.05%)
What is Grace Therapeutics TTM cash flow from operations?
The current TTM CFO of GRCE is -$11.81 M
What is the all time high TTM CFO for Grace Therapeutics?
Grace Therapeutics all-time high TTM cash flow from operations is -$805.50 K
What is Grace Therapeutics TTM CFO year-on-year change?
Over the past year, GRCE TTM cash flow from operations has changed by +$1.76 M (+12.94%)